Tumonrgenesis is considered to be a multistep process (Fearon and Vogelstein, 1990) . Most human colorectal carcinomas arise from pre-existing benign adenomatous polyps or adenomas: the adenoma-carcinoma sequence (Morson, 1962) . The existence and availability of these recognisable premalignant stages provide an opportunity to examine human colorectal carcinogenesis and tumour progression. Familial adenomatous polyposis coli (FAP) is a dominantly inherited autosomal disorder, characterised by an early onset of multiple adenomatous polyps in the colorecturm, which, when untreated, will inevitably lead to colorectal carcinoma.
Cell migration and invasion during tumor progression involve the temporary degradation of components of the extracellular matrix and basement membrane by proteolytic enzymes. Plasmin is a proteinase able to catalyse the breakdown of a broad range of extracellular matrix proteins. The proteolytic activity of plasmin is controlled by a complex cascade of interactions involving activators, receptors and inhibitors (Dan0 et al., 1985; Vassalli et al., 1991 (De Bruin et al.. 1988; Sier et al., 1991a; Pyke et al., 1991a,b) .
In the present study normal tissue, adenomatous polyps, and carcinomas were collected from patients operated on because of familial adenomatous polyposis coli. The contents of plasminogen activators and inhibitor type 1 were determined in homogenates of the tissues with several techniques and in adenomas related to the diameter, which was found in other studies to be correlated with the onset of malignancy (Vogelstein et al., 1988; Fearon and Vogelstein. 1990 ELISA for plasminogen activator inhibitor txpe I Total plasminogen activator inhibitor type I antigen, i.e. latent, active and complexed, was determined using the Tintelize PAI-I ELISA (Biopool, UmeA, Sweden) without prior denaturation of the samples as described previously (Sier et al., 1991b) . In order to increase the sensitivity of the assay, in particular for normal tissue samples, volumes of up to 80 tL were used, resulting in a detection limit of 0.3 ngmlpi as indicated by the manufacturer.
Zymographv
Tissue extracts were incubated for 1 h (2% SDS, 37C) to induce activator activity in plasminogen activatorlinhibitor complexes (Levin, 1983) . Electrophoresis of the samples took place on 10% polyacrylamide gels with sodium dodecyl sulphate (SDS-PAGE). Plasminogen activator activities were visualised on agarose underlay gels containing plasminogen and fibrin (Granelli-Piperno and Reich, 1978 
Results
Within the normal colon no significant differences in the plasminogen activator levels were detected in relation to the location of the tissue. Therefore, the mean value of the whole colon per patient is given (n = 15).
The mean plasminogen activator levels, both activity and antigen, in normal and neoplastic colonic tissue from patients with polyposis coli are shown in Figure 1 . Significant differences were found between normal mucosa and neoplastic tissues for both plasminogen activators. Urokinase-type plasminogen activator levels were 2-to 4-fold increased and tissue-type plasminogen activator levels were approximately 3-fold decreased in carcinomatous tissue compared with normal mucosa. In general. plasminogen activator levels in homogenates of adenomatous polyps were in between normal and carcinomatous tissue values. As expected, the calculated ratio of the increased urokinase-type plasminogen activator antigen concentration and the decreased tissue-type plasminogen activator antigen level in tumor tissue homogenates was significantly increased in comparison with normal mucosa (Table I) . With respect to plasminogen activator inhibitor type 1, normal mucosa and adenomas were found to have low concentrations of this inhibitor compared with the carcinomas (Table I) .
Tissue-type plasminogen activator activity was found to decrease with increasing size of the adenomas (R = -0.47, P <0.0001), in line with the changes seen in the normal mucosa-adenoma-carcinoma sequence (R = -0.58, P < 0.0001; Figure 2 Neoplastic tissues from patients with familial adenomatous polyposis coli were found to have high levels of urokinasetype plaminogen activator and type 1 inhibitor, and decreased levels of tissue-type plasminogen activator compared with normal-appearing colonic mucosa of the same patients. The changes in neoplastic polypos issue were similar to those found in our previous studies of patients with solitary sporadic adenomas and carcinomas of the colon (De Bruin et al., 1988; Sier et al., 1991b) . Many in vitro studies have been published on the contribution of urokinase-type plasminogen activator in physiological processes. In addition to the proteolytic capacity, urokinase is able to activate growth factors such as hepatocyte growth factor and transforming growth factor P, and to influence the proliferation of (tumor) cell lines in an autocrine fashion (Kirchheimer et al., 1987; Sato et al., 1990; Gelister et al., 1990) . Furthermore, the expression of the urokinase-type sminogen activator has been shown to be related to the cytoskeletal organisation of the cell (Frixen and Nagamine, 1993; Lee et al., 1993) . In a study with 171 polyps from 20 FAP patients, large adenomas (>0.5 cm) showed a higher level of cell proliferation than smaller adenomas, with no difference in the grade of dysplasia between the two groups (Quirke et al., 1988 (Friedman et al., 1985) . Moreover, disruption of the microfilament structure of cultured cells has been shown to inhibit the production of tissue-type plasminogen activator and to stimulate production of the urokinase-type plasminogen activator, inhibitor type 1 and other proteinases (Unemori and Werb, 1986; Botteri et al., 1990; Santell et al., 1992) . Genesis of adenomatous polyps in polyposis coli is characterised by increased cell proliferation, a process which is closely related to cell migration and cell growth. The urokinase-type plasminogen activator has been shown to be involved in a great number of processes of this kind and is also found to be present in increased amounts in colorectal adenomas and carcinomas of patients with or without polyposis coli. Further studies of the plasminogen activation system in tissue from these patients, in which successive stages of (pre)malignancy are present in one patient, could make an important contribution to the understanding of the mechanism of plasminogen activation in human colorectal carcinogenesis.
